Anne Mary Freeman

Title: Anne Mary Freeman: Innovator in Complement Receptor Therapeutics

Introduction

Anne Mary Freeman is a distinguished inventor located in Bucks, GB, recognized for her contributions to the field of biochemistry and therapeutic innovations. With a total of three patents to her name, her work primarily revolves around the preparation and therapeutic use of sialylated glycoforms of soluble Complement Receptor type 1 (sCR1). Her innovations hold promise for the treatment of various medical conditions, including inflammation and transplant rejection.

Latest Patents

Freeman's latest patents demonstrate her expertise and focus on advancing therapeutic methodologies. The first patent, titled "Preparation and use of sialylated glycoforms of soluble complement," outlines methods for producing preparations of recombinant soluble Complement Receptor type 1 (sCR1). These preparations are particularly effective for treating allograft or xenograft rejection, inflammatory diseases, inappropriate complement activation, and conditions related to thrombosis or shock states. The preferred formulations utilize sCR1 glycoforms that are sialylated, exhibit a pI of less than or equal to 5.1, or have a sialic acid to mannose molar ratio of greater than or equal to 0.25.

In her second patent, "Therapeutic methods employing sialylated glycoforms of soluble," Freeman further elaborates on therapeutic applications using sCR1 glycoforms. This patent emphasizes the use of sialylated variants of sCR1 for effectively addressing inflammation, complement activation issues, and thrombotic shock conditions.

Career Highlights

Anne Mary Freeman has had an impactful career, during which she has made significant contributions to biotherapeutics. She has worked with notable organizations, including T Cell Sciences, Inc. and SmithKline Beecham Corporation. Her innovative work has positioned her as a key player in the biotechnology sector, influencing the future direction of therapeutic development.

Collaborations

Throughout her career, Freeman has collaborated with esteemed colleagues, such as Henry C. Marsh and Richard A. Smith. These collaborations have fostered an environment of innovation and creativity, leading to advancements in the understanding and application of Complement Receptor therapeutics.

Conclusion

Anne Mary Freeman continues to be an influential inventor in her field, with her patented work paving the way for new therapeutic approaches that could significantly improve patient outcomes. Her dedication to advancing biotherapeutics showcases the impactful role of inventors in the scientific community and underlines the importance of continued innovation in healthcare.